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Abstract 
 
 
 
In autoimmune disorders such as Multiple Sclerosis (MS) one of the 
determining alteration is the breakdown of self-antigen immune-tolerance. 
Peripheral immune tolerance is maintained, at least in part, by Regulatory T 
cells (Treg). Several studies have shown that either defects in the frequency or 
the suppressive capacity of Treg cells can contribute to the development of 
break of self-tolerance, and that in animal models of autoimmunity, adoptive 
transfer of Treg cells was able to stop disease process (1). Treg cells are known 
to be anergic in vitro to T cell receptor-induced (TCR) stimulation and this 
state correlates with their in vitro suppressive capacity (2). It has been reported 
that there are differences in the number of Treg cells in MS patients when 
compared with healthy controls (3). However there is also extensive evidence 
indicating a defect in the suppressive function of Treg cells from MS patients 
(4). In previous studies we showed that Treg cells produce an higher amount of 
leptin when compared with effector T cells and that leptin acts as a negative 
signal for the proliferation of Treg cells (5). In vitro leptin neutralization results 
in Treg cells proliferation (5). Although in last few years several studies have 
been performed to understand the molecular mechanism leading to 
autoimmune disorders development, there are no surrogate markers to predict 
the clinical progression of autoimmune diseases and the clinical response to the 
classical therapeutic regimes.  
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Introduction 
 
 
Regulatory T cells 
 
Regulatory T (Treg) cells expressing the transcription factor forkhead box P3 
(FOXP3) are key players in the maintenance of peripheral self tolerance and 
immune homeostasis. Their dysfunction (for example, owing to FOXP3 gene 
mutation) causes fatal autoimmune disease, immunopathology and allergy (1). 
FOXP3+ Treg cells, most of which are CD4+ T cells that express CD25 (the 
interleukin-2 (IL-2) receptor α-chain), can suppress the activation, proliferation 
and effector functions — such as cytokine production — of a wide range of 
immune cells, including CD4+ and CD8+ T cells, natural killer (NK) and NKT 
cells, B cells and antigen-presenting cells (APCs) in vitro and in vivo (1). This 
unique ability to control immune responses makes FOXP3+ Treg cells central 
in the prevention of autoimmune disease, immunopathology and allergy, as 
well as in the maintenance of allograft tolerance and fetal–maternal tolerance 
during pregnancy (6). As a double-edged sword, FOXP3+ Treg cells can also 
suppress antitumour immune responses and favour tumour progression. Human 
Treg cells were first characterized as CD4+CD25+ T cells in 2001 by several 
groups (7-9)  based on the finding in 1995 that mouse Treg cells constitutively 
express CD25 (10). Similarly, in 2003, Foxp3 was described as a master 
control gene for mouse Treg cell development and function (11-13), and 
subsequent studies have confirmed FOXP3 as a specific marker for human 
Treg cells (14). It has been show that the normal thymus produces T cells with 
an autoimmune-preventive function. Direct evidence of the thymic origin of 
Treg cells and their persistence in the periphery was shown by the adoptive 
transfer of thymocyte or peripheral T cell suspensions depleted of CD4+CD25+ 
T cells, which results in the development of various autoimmune diseases in 
syngeneic T cell-deficient mice (10,15,16) Ontogenically, CD4+CD25+ T cells 
become detectable in the periphery ~3 days after birth, indicating that neonatal 
thymectomy abrogates thymic production of Treg cells (15,17). Furthermore, 
depletion of peripheral FOXP3+ T cells for a limited time period results in 
autoimmunity in mice (17,12). Based on these findings, thymus-derived 
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CD4+FOXP3+ T cells are thought to be 'natural' Treg cells. Thymic 
development of Treg cells requires high-affinity interactions between their T 
cell receptor (TCR) and self-peptide–MHC complexes presented by thymic 
stromal cells (18).  
 
 
 
            
 
Figure 1. CD4+CD25+ T cells seem to be members of a unique lineage of T cells that are 
selected during the process of T-cell differentiation in the thymus. It remains unclear where 
and when this occurs. A)  One possibility is that CD25+ T cells acquire expression of CD25 
and suppressor function in the thymic medulla, where they recognize self-antigens that are 
presented on MHC class II molecules by medullary dendritic cells (DCs) in a process that is 
known as 'altered negative selection'. They then migrate directly to peripheral lymphoid 
tissues. B) Studies with the K14 transgenic mouse have indicated that CD25 expression and 
suppressor function is acquired at a much earlier stage of differentiation in the thymic cortex 
during the process of positive selection on cortical epithelial cells. Some of these CD25+ T 
cells then undergo a process of negative selection on bone-marrow-derived cells (such as DCs) 
in the medulla and die by apoptosis, but others are allowed to migrate to peripheral lymphoid 
tissues, according to the affinity of their TCR for self-antigens. TCR, T-cell receptor; Ts, 
suppressor T cell. 
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These cells also provide co-stimulatory signals that are necessary for their 
development as shown by the decrease in the number of Treg cells generated in 
the thymus following loss of CD40 or CD28 expression (1). Furthermore, both 
IL-2 and IL-7 in the thymic microenvironment are required for Treg cell 
development in mice (19). Given the known similarities between mouse and 
human thymocyte development (20), it is likely that many of these 
requirements for Treg cells in mice are similar for human Treg cell 
development. The key role of FOXP3 gene in the maintenance of self tolerance 
was first shown in scurfy mice and subsequently in patients with 
immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) 
syndrome as the causative genetic anomaly that results in severe autoimmune 
diseases and allergy, which resemble the diseases observed following depletion 
of CD4+CD25+ Treg cells in rodents (21-23). Importantly, ectopic expression 
of FOXP3 in naive mouse CD4+ T cells confers suppressive activity and 
induces the expression of Treg cell-associated signature molecules such as 
CD25, cytotoxic T lymphocyte antigen 4 (CTLA4) and glucocorticoid-induced 
TNF-receptor-related protein (GITR) (11-13). Expression of these receptors 
also correlates with FOXP3 expression in human CD4+ T cells (24). This 
induction of suppressive activity in conventional T cells by ectopic FOXP3 
expression, together with the development of autoimmune disease in FOXP3 
mutant or deficient mice, indicates that FOXP3 is a master regulator for Treg 
cell differentiation and function (25). Although the transient expression of 
FOXP3 does not enable suppression, sustained FOXP3 expression by activated 
T cells can confer regulatory competence (26-28). Furthermore, in human 
CD4+ Treg cells, stable and high FOXP3 expression is required for suppressive 
function, and loss of FOXP3 expression over time owing to long-term culture 
decreases the ability of formerly potent Treg cells to suppress (29,30). Human 
FOXP3 is expressed by both activated and regulatory T cells in the peripheral 
blood, as are other known Treg cell biomarkers such as CD25, CTLA4, GITR 
and CD95 (also known as FAS). This upregulation of FOXP3 in activated T 
cells could be one component of the homeostatic programme initiated by these 
cells to exert negative feedback during the course of an immune response. 
Recently, several groups showed that the lack of cell surface CD127 (also 
known as IL-7 receptor α-chain) can be a useful alternative to CD25 for the 
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delineation and purification of human Treg cells: FOXP3 expression and 
suppressive ability are enriched in CD4+ T cells that express low levels of 
CD127 (31,32). Treg cells have potent in vitro suppressive activity and show 
hyporesponsiveness following activation in vitro (7,8) analysis of effector Treg 
cell turnover in vivo indicates that these cells undergo rapid turnover, which is 
not indicative of a long-lived memory T cell population (33). The precise 
molecular mechanisms of suppression by human Treg cells remains to be 
determined, although in vitro and in vivo mouse studies have implicated 
several mechanisms. These include modulation of the cytokine 
microenvironment, metabolic disruption of the target cell, alteration of DC 
activating capacity and cytolysis (1,34,35). For example, human Treg cells can 
be suppressive in vitro even in the absence of APCs (7), indicating that target 
cell suppression can occur through direct contact between Treg and effector T 
cells. A recent study in mice has shown that CTLA4 is crucial for the 
suppressive function of FOXP3+ Treg cells both in vitro and in vivo (36). 
CTLA4 expressed by Treg cells can modulate CD80 and CD86 expression by 
DCs and thereby inhibit the activation of effector T cells. Dysfunctional Treg 
cells can be a cause of autoimmune disease, allergy and immunopathology. But 
it remains to be determined how these cells are involved in the 
pathophysiology of common immunological diseases such as autoimmune 
disease (6,37). 
 
 
Leptin as an immunoendocrine mediator  
 
Leptin is a 16-kDa nonglycosylated protein encoded by the ob gene, which is 
located on human chromosome 7 and on mouse chromosome 6. In humans and 
mice, mutations of the ob gene are associated with hyperphagia and obesity, 
reduced energy expenditure, and other reproductive, neuroendocrine, and 
metabolic dysfunctions. Serum leptin is usually higher in obese individuals and 
has a strong sexual dimorphism—higher in females than males matched by age 
and body weight (38). Leptin is classically considered a hormone, as it 
regulates the balance between food intake and energy expenditure, signaling to 
the brain the changes in stored energy. Serum leptin is correlated directly with 
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the body-fat stores, increasing with fat accumulation and decreasing during 
fasting. Leptin gene expression is regulated by several factors, including other 
hormones such as insulin, glucocorticoids, and sex hormones. Insulin 
stimulates leptin secretion during feeding, and a decrease in insulin levels 
anticipates a fall in leptin during starvation. Glucocorticoids also operate 
synergistically with insulin in the secretion of leptin from cultured adipocytes, 
although an inverse relationship between leptin and glucocorticoids is 
generally observed (38). Finally, leptin expression is inhibited by testosterone, 
increased by ovarian sex steroids, and directly influences the hypothalamic-
pituitary-adrenal axis, the reproductive system, hematopoiesis, and 
angiogenesis. A series of studies has linked the immune and neuroendocrine 
systems. Leptin is one of the mediators that is common to the neuroendocrine 
and immune systems (39). In the immune system, leptin, together with C-
reactive protein (CRP), IL-1, and IL-6, can act as an early acute-phase reactant, 
produced at high levels during inflammation, sepsis, and fever, and it can be 
induced by other inflammatory mediators such as TNF and IL-1 (39-41). 
However, although these findings have been demonstrated in several systems, 
other studies have not found increased leptin in inflammatory conditions in 
humans, including acute experimental endotoxaemia, newborn sepsis, and HIV 
infection and during anti-inflammatory therapy (42-44). The neuroendocrine 
role of leptin is most evident in conditions such as fasting—during which the 
production of leptin by adipose tissue is markedly reduced—or in relation to 
the effects of sex hormones on its production (testosterone reduces the 
secretion of leptin, whereas estrogens increase its production). The link 
between leptin and sex hormones is also indicated by the marked gender 
dimorphism, manifested by a higher serum concentration in females than in 
males with similar body-fat mass (38). The fact that leptin has effects on 
neuroendocrine and immune systems should not come as a surprise, given the 
functional connection and anatomical contiguity between adipocytes and 
lymphoid cells (45). Morphologically, aggregations of lymphoid tissue, 
including the lymph nodes, thymus, and bone marrow, are associated with 
adipose tissue (45). Fat deposits do not simply have a structural, metabolic, and 
heat-insulating function but also provide a microenvironment that helps the 
immune system to sustain immune responses. In particular, lymphoid and 
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adipose tissues interact locally through common mediators known as 
adipokines, adipocyte-derived molecules that bridge metabolism, and immune 
homeostasis (these molecules include leptin, adiponectin, chemokines, and 
other proinflammatory cytokines).  
 
 
Leptin in innate and adaptive immunity  
 
Humans with congenital leptin deficiency have a much higher incidence of 
infection-related death during childhood (46), whereas recombinant human 
leptin administration in children with congenital leptin deficiency normalized 
absolute numbers of naive CD4CD45RA T cells and nearly restored the 
proliferation response and the cytokine release profile from their lymphocytes 
(47). Studies in mice have shown that the effect of leptin on the immune 
system is direct and indirect, i.e., via modulation of central or peripheral 
pathways. The effects of leptin on adaptive immune responses have been 
investigated extensively on human CD4+ T cells. Addition of physiological 
concentrations of leptin to a MLR induces a dose-dependent increase in CD4+ 
T cell proliferation (48). However, leptin has different effects on proliferation 
and cytokine production by human naive (CD45RA+) and memory (CD45RO+) 
CD4+ T cells (both of which express OBRb). Leptin promotes proliferation 
and IL-2 secretion by naive T cells, whereas it minimally affects the 
proliferation of memory cells (on which it promotes a bias toward Th1 cell 
responses). Another important role of leptin in adaptive immunity is 
highlighted by the observation that leptin deficiency in ob/ob mice is 
associated with immunosuppression and thymic atrophy—a finding similar to 
that observed in acute starvation (48). Acute caloric deprivation causes a rapid 
decrease of serum leptin concentration accompanied by reduced delayed-type 
hypersensitivity (DTH) responses and thymic atrophy, which are reversible 
with administration of leptin (48-50). The thymic atrophy in ob/ob mice (or 
wild-type, starved animals) affects the cortex of the thymus, in which most 
CD4+CD8+ T cells are found, and leptin replacement reduces the rate of 
apoptosis of such cells (49). Despite the evidence of direct effects of leptin on 
immune responses in vitro, a major problem remains whether leptin can 
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influence immune responses in vivo. This task is particularly difficult, because 
of the complexity of the network of interactions that link leptin to several 
endocrine pathways. It is notable that T cells are sensitive to the supply of 
cellular nutrients, such as glucose (51), as they do not have glycogen stores and 
therefore, depend on the import of extracellular glucose to meet their metabolic 
needs (52). By stimulating glucose uptake through ERK1/ERK2- and PI-3K-
dependent pathways, leptin might help to restore the impaired T cell function 
caused by starvation (49).  
 
 
 
 
 
 
 
Figure 2: Schematic representation of the effects of leptin on both innate and adaptive 
immunity. 
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In this context, it is worth mentioning that other long-chain helical cytokines 
similar to leptin (such as IL-3, IL-7, and IL-15) are important in promoting the 
uptake and metabolism of glucose (52). In innate immunity, leptin seems to 
promote activation of and phagocytosis by monocytes/macrophages and their 
secretion of leukotriene B4 (LTB4), cyclooxygenase 2 (COX2), NO, and 
proinflammatory cytokines (53). The products of the inducible form of 
COX2—PGs and LTs (also known as eicosanoids)—as well as NO are 
involved in the regulation of inflammation, chemotaxis, and cytokine 
production and therefore, markedly impact the immune response. Moreover, 
leptin can induce chemotaxis of neutrophils and the release of oxygen radicals 
(such as superoxide anion and hydrogen peroxide) (53). These mediators can 
be particularly harmful to cells, as they can denature proteins and damage 
membrane lipids (by peroxidation of unsaturated fatty acids), carbohydrates, 
and nucleic acids. At least in human neutrophils, leptin seems to mediate its 
effects through an indirect mechanism, probably involving the release of TNF 
from monocytes (54,55). Leptin also affects NK cell development and 
activation in vitro and in vivo (56-59). As NK cells express OBRb, and db/db 
mice have a deficit of NK cells resulting from abnormal NK cell development, 
it is possible that leptin might influence the development/maintenance of a 
normal, peripheral NK cell pool. Indeed, an important role of OBRb in NK cell 
physiology is indicated by the ability of OBRb to influence NK cell 
cytotoxicity through direct activation of STAT3 and the transcription of genes 
encoding IL-2 and perforin. Last but not least, it has recently been shown that 
leptin can stimulate the production of the growth hormone by PBMCs through 
protein kinase C- and NO-dependent pathways (59). This effect of leptin on the 
production of the growth hormone might be important in immune homeostasis, 
given the fact that this cytokine-like hormone has marked influences on 
immune responses by controlling the survival and proliferation of immune 
cells. 
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Multiple Sclerosis 
 
Multiple sclerosis (MS) is one of the most common chronic and disabling 
disorders of the central nervous system (CNS), affecting 0.05–0.15% of 
Caucasians (60). The disease usually begins in young adulthood and affects 
women more frequently than men (2:1). In 80–90% of cases, MS starts with a 
relapsing–remitting course (RR-MS).  
 
 
        
 
 
Figure 3. Possible target antigens in the white matter. Proteins of the myelin sheath, 
oligodendrocytes and neurons are possible targets of the immune response in multiple 
sclerosis. Among the candidates are myelin and neuronal antigens, and also proteins that are 
introduced into those cells by infectious agents. MAG, myelin-associated glycoprotein; MBP, 
myelin basic protein; MOG, myelin oligodendrocyte glycoprotein; PLP, proteolipid protein. 
 
 
Over time, the number of relapses decreases, but most patients develop 
progressive neurological deficits that occur independently of relapses (the so-
called secondary progressive phase). In 10–20% of patients, MS begins with a 
primary progressive course (PP-MS) without acute relapses. In general, the 
progression rate in RR-MS is comparable to that of PP-MS as soon as the 
patients enter the secondary progressive phase (61). 
 Imaging studies have revealed differences between RR-MS and PP-MS. In 
patients that suffer from RR-MS, acute CNS lesions with spontaneous 
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resolution are frequently detected, even in the absence of clinical attacks (62). 
These lesions are usually located in areas of white matter, and are often 
characterized by a disturbance of the blood–brain barrier, local oedema and 
demyelination — features that are compatible with an inflammatory process. 
By contrast, when progressing to the secondary phase and in patients with PP-
MS, such inflammatory activity is much less conspicuous (62). Global brain 
atrophy, however, is more dominant in the progressive stage and seems to 
correlate with disability (63,64). These findings indicate that early in the 
disease, ongoing inflammatory activity is present in most patients and is 
responsible for the relapsing–remitting course, whereas a distinct process 
might be operative in the progressive phase of the disease, when inflammatory 
activity diminishes despite faster evolution of disability.  
Patients disability can be measured using disability scales. In MS the most 
frequently used is Kurtzke’s Expanded Disability Status Scale (EDSS) (65). 
This scale was developed from the Disability Status Scale and is observer- 
(usually neurologist-) rated. EDSS steps 1.0 to 4.5 refer to people with MS 
who are fully ambulatory. EDSS steps 5.0 to 9.5 are defined by the impairment 
to ambulation. EDSS step 10 refers to death due to MS. 
The prevalence of MS varies significantly depending on the genetic 
background of the patient (66). MS is highly prevalent in Caucasians, but only 
rarely observed in Asians or Africans. Moreover, the risk of developing the 
disease is significantly higher in family members of patients with MS (67). By 
contrast, the prevalence in spouses and adopted family members does not differ 
from that of the general population. These findings argue for a strong genetic 
predisposition to MS, and have prompted a large number of linkage and 
association studies to identify disease loci and alleles. The results of genomic 
screens in MS indicate that a considerable number of different genes, each 
having a relatively small contribution, are involved in the susceptibility to MS 
(68,69). So far, only the human leukocyte antigen (HLA) class II alleles 
DR15/DQw6 (HLA-DRB1*1501; HLA-DQB1*0601), which code for 
molecules that participate in antigen recognition by T lymphocytes, have been 
consistently associated with MS in Caucasians (70). The most studied model of 
MS in animals is EAE, in which autoimmunity to CNS components is induced 
in susceptible strains of mice through immunization with self-antigens derived 
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from basic myelin protein. The disease is characterized by autoreactive T cells 
that traffic to the brain and to the spinal cord and injure the myelin sheaths of 
CNS, with the result of chronic or relapsing-remitting paralysis (depending on 
the antigen and the strain of mice used). It has long been known that myelin-
reactive Th1 CD4+ cells can induce and/or transfer disease, and Th1 cytokines 
are elevated in the CNS inflammatory lesions of EAE. In contrast, Th2 
cytokines typically associate with recovery from EAE and/or protection from 
the disease (71). 
 
 
 
 
Figure 4. Immune responses in multiple sclerosis. Hypothetical view of immune responses 
in acute multiple sclerosis lesions. Independent of the causative event, two steps are required to 
induce an immune response in the central nervous system (CNS): a pro-inflammatory milieu in 
the CNS, leading to upregulation of major histocompatibility complex (MHC) molecules, co-
stimulatory receptors and inflammatory cytokines and an antigen-driven acquired immune 
response. T- and B-cell responses are primed in the peripheral lymphoid tissue by antigens that 
are released from the CNS or by cross-reactive foreign antigens. Dendritic cells that present 
neural antigens are strong stimulators of T-cell responses. After clonal expansion, T and B 
cells infiltrate the CNS. Clonally expanded B cells re-encounter their specific antigen, mature 
to plasma cells and release large amounts of immunoglobulin-  (IgG) antibodies. These 
antibodies bind soluble or membrane-bound antigen on expressing cells. Clonally expanded 
CD8+ T cells also invade the brain and could encounter their specific peptide ligand, presented 
by glial or neuronal cells on MHC class I molecules. The recognition of specific MHC–peptide 
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complexes on these cells prompts direct damage to expressing cells. CD4+ T cells migrate into 
the CNS and encounter antigens that are presented by microglial cells on MHC class II 
molecules. Reactivation of these cells leads to heightened production of inflammatory 
cytokines. These cytokines attract other immune cells, such as macrophages, which contribute 
to inflammation through the release of injurious immune mediators and direct phagocytic 
attack on the myelin sheath. 
 
 
 
The leptin connection: regulatory T cells and multiple sclerosis 
 
It has been shown that leptin has an important role in controlling the anergy 
and hyporesponsiveness of regulatory T cells. A clue that leptin might be 
involved in the homeostasis of regulatory T cells came from a study showing 
that leptin is higher in serum of multiple sclerosis patients and correlated with 
reduced numbers of regulatory T cells (72). Indeed it has been reported that the 
secretion of leptin is increased in both serum and cerebrospinal fluid (CSF) of 
naive-to-treatment patients with MS, an aspect that positively correlates with 
the secretion of IFN-γ in the CSF and inversely correlates with the percentage 
of circulating Treg cells. Of note, the number of peripheral Tregs in patients 
with MS inversely correlates with the serum levels of leptin, suggesting a link 
between the number of Treg cells and leptin secretion. This observation was 
supported by another paper showing that reduction of Treg cells are likely a 
direct consequence of leptin binding to receptors on the regulatory T cells (73). 
Regulatory T cells are normally anergic and hyporesponsive to T cell receptor 
(TCR) signalling, but De Rosa et al. showed that specific neutralization of 
leptin combined with TCR signaling reversed anergy and hyporesponsiveness 
of this cellular subset. Proliferation was dependent on IL-2 but appeared to 
operate through a distinct mechanism. Interestingly, an important source of 
leptin was the regulatory T cells themselves, which both secreted leptin and 
expressed leptin receptors. Thus, leptin can mediate a negative autocrine loop 
in regulatory T cells even in the absence of exogenous leptin. The reversal of 
anergy by leptin neutralization was associated with phosphorylation of ERK1/2 
kinase and rapid degradation of the cell-cycle inhibitor p27kip1 (73). 
Importantly, regulatory T cells that were expanded in the presence of leptin 
antibody retained their immunosuppressive phenotype for up to 8 days in 
culture. In vivo results supported a role for leptin-receptor signaling in 
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impaired regulatory T cell proliferation. Mice with genetic deficiency of leptin 
(ob/ob) had higher percentages and absolute numbers of circulating regulatory 
T cells (74). Furthermore, wild-type regulatory T cells adoptively transferred 
into leptin-deficient mice expanded substantially more than those transferred 
into wild-type mice. Thus, regulatory T cells proliferated better in a leptin-poor 
environment. Consistent with that conclusion, treatment of wild-type mice with 
leptin-neutralizing antibody produced an expansion of regulatory T cells. In 
contrast, administration of leptin reduced the numbers of regulatory T cells in 
leptin-deficient mice to amounts equivalent to those in wild type mice (72). 
Given the proven role of regulatory T cells in protection from autoimmune 
diseases, it appears that at least part of the resistance to autoimmune disease in 
leptin-deficient and leptin-receptor-deficient mice may be due to increased 
numbers of regulatory T cells. De Rosa et al. also showed that although leptin 
had a negative impact on regulatory T cell proliferation, it had the opposite 
effect on conventional CD4+ T cells. In contrast to results from regulatory T 
cells, in vitro expansion of conventional CD4+CD25- T cells by stimulation 
with CD3 and CD28 antibodies was markedly less effective on cells lacking 
the leptin receptor than on wild-type cells. Furthermore, neutralizing leptin 
reduced the proliferation of conventional CD4+CD25- T cells in vitro. These 
effects were not peculiar to anti-CD3 and anti-CD28 stimulation because 
similar findings were made when stimulation was done with a pancreatic 
autoantigen in the nonobesediabetic-mouse model coupled with a leptin-
receptor mutation. Thus, the increased resistance to autoimmune disease and 
susceptibility to infection in leptin-deficient (ob/ob) and leptin-receptor 
deficient (db/db) mice is likely a combined effect from enhancement of the 
immune system regulatory arm with a concomitant impairment of the effector 
arm. Moreover it has been shown that leptin is involved in the induction and in 
the progression of EAE the animal model of MS (74,75). Leptin-deficient mice 
are resistant to induction of active and adoptively transferred EAE. This 
protection is reversed by leptin administration and associates with a switch 
from Th2- to Th1-type responses and a IgG1-to-IgG2a isotype switch. 
Similarly, in susceptible wild-type C57BL/6J mice, leptin worsens disease by 
increasing IFN-γ release and IgG2a production (75). Importantly, a surge of 
serum leptin anticipates the onset of clinical manifestations of EAE. The peak 
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of serum leptin correlates with inflammatory anorexia, weight loss, and the 
development of pathogenic T cell responses against myelin. 
Lymphomononuclear infiltrates in the CNS of EAE mice indicate in situ 
production of leptin in active, inflammatory lesions, thus representing a 
significant local source of leptin (75). Systemic and/or in situ leptin secretion 
were instead lacking in EAE-resistant mice. Taken together, these data suggest 
an involvement of leptin in CNS inflammation in the EAE model of MS 
probably correlated to the modulation of Treg cells function. 
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Aim of the study 
 
Multiple sclerosis is an autoimmune disease characterized by chronic 
inflammation of the central nervous system. The pathology of MS is largely 
attributed to autoreactive effector T cells that penetrate the blood-brain barrier 
and damage CNS myelin. Active suppression by regulatory T (Treg) cells 
plays a key role in the control of self-antigen-reactive T cells and the induction 
of peripheral tolerance in vivo. In particular, the importance of antigen-specific 
Treg cells in conferring genetic resistance to organ-specific autoimmunity and 
in limiting autoimmune tissue damage has been documented in many disease 
models including MS.  
In this study, we aimed at evaluating the proliferative potential of Treg cells in 
MS patients, to determine whether during MS there could be an alteration in 
regulatory T cells homeostatic processes. Since it has been shown that 
proliferation of Treg cells is inhibited by the adipocytokine leptin and in vitro 
leptin neutralization results in Treg cells proliferation, we investigated the 
capacity of Treg cells, purified from RR-MS patients, to expand upon leptin-
neutralization and we compared the proliferation rate of these cells with that 
observed in healthy controls. 
Despite intensive studies to understand the alterations occurring during 
autoimmune diseases, so far there are no surrogate markers of immune 
tolerance either capable of “measuring” self-antigen tolerance in MS or to 
anticipate clinical progression of the disease. In this report, we evaluated the 
relationship between the proliferative potential of Treg cells and clinical 
progression in MS to determine whether this marker could be related with the 
state of immune tolerance in MS patients.  
More in detail, we analyzed the relationship between the in vitro proliferative 
capacity of Treg cells and the EDSS score of MS patients to understand 
whether the major or minor proliferation of Treg cells could be related with a 
better or worse progression of disease curse. This assay was named 
“TregsAssay”, and our findings suggest the use of the in vitro Treg cells 
proliferation index as marker for evaluation of immunological tolerance in MS 
and autoimmunity. 
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Material and methods  
 
Subjects 
All MS patients and controls were recruited at the Università di Napoli 
“Federico II.”  For Treg proliferation assay we included in the study 71 
patients with MS defined according to the criteria of McDonald et al (76) and 
40 healthy controls. We additional included for hMBP-specific short-term T 
cells lines 52 patients and 30 healthy controls. All MS patients had RR-MS and 
an expanded disability status score of ≤ 7.0. All blood samples from patients 
and controls were collected at 9.00 am in heparinised vacutainers (BD 
Biosciences, Milan, Italy) and processed within the following 3 hours.  
 
Regulatory T cell Purification, Cultures, and Proliferation Assays 
Human CD4+CD25hi CD127- Regulatory T cells were isolated from MS 
patients and from healthy controls. Human CD4+CD25hiCD127- and 
CD4+CD25− T cells were purified from PBMCs from buffy coats of human 
healthy donors or from peripheral blood of MS patients by high-performance 
cell sorting (MoFlo, Dako) after staining with FITC anti-human CD4 (BD 
PharMingen, clone RPA-T4), PE anti-human CD25 (BD PharMingen, clone 
M-A251), APC anti-human CD127 (R&D Systems, clone 40131), or magnetic 
cell separation with Dynabeads Regulatory T Cell Kit (Invitrogen). Soon after 
isolation, CD4+CD25hiCD127− cells were rapidly cleaned with Detach reagent 
(Invitrogen) to remove surface-bound CD25 mAb and beads. Antibody/bead-
free cells were 95%–98% pure by FACS analysis, and >95% expressed FoxP3. 
Cells were cultured (1 × 104 cells/well) in round-bottom 96-well plates 
(Becton-Dikinson Falcon,) with RPMI medium supplemented with 100 U/ml 
penicillin, 100 µg/ml streptomycin (all from Life Technologies Inc) and either 
5% patients autologus serum or 5% AB human serum (Sigma-Aldrich). Cells 
were stimulated for 3 days in the presence of anti-CD3/CD28 Dynabeads (0.1 
bead/cell) (Invitrogen). For in vitro blocking experiments, human leptin-
neutralizing mAb (R&D system) was used at a final concentration of 20 
mg/ml. On the last day, [3H]thymidine (0.5 µCi/well) (Amersham-Pharmacia 
Biotech) was added to the cultures and cells harvested after 12 hr. 
Radioactivity was measured with a β-cell-plate scintillation counter (Wallac). 
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IL-2 Measurement 
IL-2 measurement was done with a human IL-2-specific ELISA kit purchased 
from BD-bioscience and measurements was performed according to the 
manufacturer’s instructions. All serum samples from MS patients and controls 
were collected and stored at −80 °C before the analysis. Supernatants were 
collected from each experimental point 24 hours after starting stimulation.  
 
Leptin measurement  
A human leptin ELISA kit (R&D Systems, Minneapolis) were used according 
to the manufacturer's instructions. 
 
Ki67 expression  
Freshly isolated PBMCs by Ficoll Hypaque gradient centrifugation from MS 
patients and healthy controls were immunostained with the anti-CD4-Pe-Cy5 
and anti-CD25-APC monoclonal antibodies from BD Biosciences. Thereafter 
cells were washed, fixed, permeabilized (fixation-permeabilization buffer, 
eBioscience) and stained with anti-Foxp3-PE (eBioscience) and anti-Ki67-
FITC (BD Biosciences) monoclonal antibodies. Cells were analyzed 
employing the Diva software and a FACSCanto (Becton-Dickinson). 
 
Human Myelin Basic Protein (hMBP) short-term T cell lines. 
 hMBP-specific short-term T-cell lines were generated from PBMC from MS 
patients and healthy controls. PBMC were separated by Ficoll Hypaque 
gradient centrifugation and were cultured (1 x 106 cells/well)  for 7 days in 48-
well plates with RPMI medium supplemented with 100 U/ml pennicillin, 100 
mg/ml streptomycin and either 5% autologous serum for patients or 5% AB 
human serum for controls. Cells were stimulated for 7 days in presence of 
hMBP (25 mg/ml) alone or in presence of hMBP plus human leptin- 
neutralizing antibody (20 mg/ml) or in the presence of 50 U/ml of human 
recombinant interleukin-2 (r-IL-2). On the last day FACS analysis was 
performed. FITC-anti-human-Ki67 and PeCy5-anti-human-CD4 were from BD 
Biosciences; the anti-human Foxp3 staining set was from eBiosciences; APC-
anti-human-CD25 was from Miltenyi. 
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Statistical analysis  
 
Comparisons between MS patients and healthy controls were evaluated using a 
non-parametric Mann-Whitney test. Comparisons between patients were 
evaluated using a matched paired t test. These statistical analyses were 
performed using the program GraphPad InStat3 (Abacus Concepts, Cary, NC). 
The difference in the Treg cells fold increase in proliferation values among 
patients classified according to their clinical status (EDSS) has been evaluated 
using the non parametric Kruskal-Wallis procedure followed by the Mann-
Whitney U test with Bonferroni correction. In order to evaluate the relationship 
between the dependent variable (EDSS score) and the fold increase in 
proliferation of Treg cells upon leptin neutralization, a quantile regression 
model was fitted. To investigate the biological correlations between the 
different variables analyzed in this study, the Spearman correlation coefficient 
was computed. Due to the large number of correlations involved and in order 
to control the familywise error rate at level alpha, the adaptive Bonferroni 
procedure described in Guo W. (77) was used. P < 0.05 was considered 
statistically significant. 
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Results 
 
Treg cells from MS patients show a reduced in vitro hyporesponsiveness.  
 
CD4+CD25highCD127- regulatory T cell (Treg) were purified from human 
healthy donors and from MS patients. Firstly we evaluated the in vitro anergic 
state of Treg cells purified from healthy controls and MS patients upon anti-
CD3 and anti-CD28 stimulation. As expected, Treg cells purified from healthy 
donors were completely hyporesponsive to in vitro TCR mediated stimulation. 
On the contrary, Treg cells from MS patients showed a reduced in vitro 
hyporesponsiveness resulting in a partial cell proliferation (Fig 5A). This 
phenomenon associated with low albeit significant IL-2 secretion when 
compared with controls (Fig 5B).  Interestingly no significant differences in the 
proliferation and IL-2 production of effectors T cells (CD4+CD25-) were 
detected between controls group and MS patients (Fig 8A and B). 
 
 
 
 
 
Figure 5. Treg cells from MS patients show a reduced in vitro hyporesponsiveness. (A) 
Proliferation of CD4+CD25highCD127- T cells from healthy controls and MS patients stimulated 
with anti-CD3 and anti-CD28. (*p = 0.0012). (B) IL-2 secretion by CD4+CD25highCD127- Treg 
cells from healthy controls and MS patients stimulated with anti-CD3 and anti-CD28. (*p = 
0.003). The data are shown as mean ± SEM. 
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Treg cells from MS patients show a reduced anti-leptin-induced 
proliferation and IL-2 secretion. 
 
To address the effect of leptin neutralization on Treg cells purified from MS 
patients, we compared proliferation of Treg cells purified from MS patients 
with proliferative potential of Treg cells from healthy controls. Leptin 
neutralization resulted in proliferation of Treg cells purified from both healthy 
subjects and patients (Fig 7A). However, Treg cells from MS patients showed 
a significantly lower proliferative capacity upon leptin neutralization. Indeed 
Treg cells from MS patients showed a lower fold increase in proliferation upon 
leptin neutralization when compared with healthy controls (Fig 7B). Since 
leptin-mAb-induced Treg cells proliferation is IL-2 dependent (75), to test 
whether the reduced expanding capacity of Treg cells from MS patients could 
be ascribed to a decrease in IL-2 production, we measured Treg cells IL-2 
secretion upon leptin neutralization and found that also IL-2 secretion was 
impaired in MS patients (Fig 7C). 
Finally, in agreement with previous findings (74) we found that leptin 
production was significantly increased in serum of MS patients (Figure 6A). 
Moreover  we confirmed that Treg cells from healthy controls showed higher 
leptin production than did CD4+CD25− effector T cells during anti-CD3 and 
anti-CD28 stimulation (Figure 6B) and we showed that the amount of leptin 
secreted by Treg cells from MS patients was similar to that observed in healthy 
controls (Figure 6B). Addition of neutralizing leptin monoclonal antibody 
(mAb) to Treg cells cultures stimulated with anti-CD3 and anti-CD28, reverses 
the hyporesponsiveness and promotes Treg cells proliferation in a dose-
dependent fashion (75). 
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Figure 6. Serum leptin level and Treg cells leptin production in healthy controls and MS 
patients. (A) Serum Leptin level in healthy controls and MS patients. The data are shown as 
mean±SEM (*p=0.0006). (B) Regulatory T cells secrete an higher amount of leptin with 
respect to effector T cells in both controls and MS patients. Leptin secretion by Treg cells  and 
effector T cells, stimulated with anti-CD3 and anti-CD28, from Healthy controls and MS 
patients. The data are shown as mean ± SEM (*p < 0.0001). 
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Figure 7. Regulatory T cells from MS patients exhibit reduced proliferation and IL-2 
production upon leptin neutralization. (A) Proliferation of CD4+CD25highCD127- Treg cells 
from healthy controls and MS patients stimulated with anti-CD3 and anti-CD28 in the presence 
or absence of leptin mAb. The data are shown as mean ± SEM (*p < 0.0001, **p = 0.0012, 
***p = 0.021). (B) Fold increase in proliferation of CD4+CD25highCD127- Treg cells from 
healthy controls and MS patients upon leptin neutralization. The graph shows the mean of 
proliferation of  Treg cells upon leptin neutralization with respect to the mean of proliferation 
of Treg cells without leptin neutralization. (C) IL-2 secretion by Treg cells from healthy 
controls and MS patients stimulated with anti-CD3 and anti-CD28 in the presence or absence 
of leptin mAb. The data are shown as mean ± SEM (*p = 0.0008, **p = 0.003, ***p < 0.0001). 
(D) Fold increase in IL-2 secretion by Treg cells from healthy controls and MS patients upon 
leptin neutralization. The graph shows the mean of IL-2 secretion by Treg cells upon leptin 
neutralization with respect to the mean of IL-2 secretion by Treg cells without leptin 
neutralization.  
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Figure 8. Effector T cells proliferation and IL-2 production. (A) Proliferation of 
CD4+CD25- effector T cells from healthy controls and MS patients stimulated with anti-CD3 
and anti-CD28 in the presence or absence of leptin mAb. (B) IL-2 secretion by CD4+CD25- 
effector T cells from healthy controls and MS patients stimulated with anti-CD3 and anti-
CD28 in the presence or absence of leptin mAb. The data are shown as mean ± SEM. 
 
 
Loss of linear correlation between anti-leptin induced Treg cells 
proliferation and IL-2 secretion in MS patients. 
 
We next compared Treg cells anti-leptin-induced proliferation with anti-leptin-
induced IL-2 production in both controls and patients. The fold increase in 
proliferation and the fold increase in IL-2 production of Treg cell, upon leptin 
neutralization, were evaluated. In healthy controls there was a linear 
correlation between Treg cells anti-leptin induced proliferation and anti-leptin 
induced IL-2 production (Fig 9A, right panel), indicating that IL-2 production 
supports their own anti-leptin-induced proliferation. In MS patients there was a 
loss of this correlation (Fig 9A, left panel) and thus Treg cells fold increase in 
proliferation upon leptin neutralization was not correlated with a concomitant 
increase in IL-2 production, suggesting a disruption of this axis in MS We next 
evaluated IL-2 serum level in both controls and MS patients. MS patients 
showed a lower IL-2 concentration when compared to healthy controls (Fig 
9B).  
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Figure 9. Anti-leptin induced proliferation of Treg cells from MS patients is not 
correlated with anti-leptin induced IL-2 production (A) The graphs show the correlation 
between the fold increase in proliferation of Treg cells and the fold increase in IL-2 secretion 
by Treg cells upon leptin neutralization in healthy controls (left panel) and MS patients (right 
panel). (B) Serum IL-2 levels in healthy controls and MS patients. The data are shown as mean 
± SEM (*p = 0.02).  
 
 
Inverse correlation between Treg cells Expansion Index and MS clinical 
severity. 
 
We next evaluated the relation between the proliferative capacity of Treg cells 
isolated from MS patients upon leptin neutralization and the clinical status of 
MS patients. Disease severity of each patient was assessed clinically using the 
Expanded Disability Status Scale (EDSS), a method of quantifying disability in 
multiple sclerosis (67). We divided all patients in three groups on the basis of 
their EDSS value. We observed that MS patients with a lower EDSS displayed 
an higher proliferative capacity of Treg upon leptin neutralization when 
compared with patients whose clinical score was much more severe (Fig. 10, 
left panel) indicating that the progression of pathology compromises the 
proliferative potential of Treg cells or that impaired Treg cells expansion could 
be associated with a worse clinical progression of MS. In order to evaluate the 
relationship between the EDSS score (dependent variable) and the fold 
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increase in proliferation of Treg cells upon leptin neutralization, a quantile 
regression model was fitted. The estimated quantile regression coefficients for 
the different quantiles of the EDSS distribution, along with the 95% confidence 
bands, are shown in Figure 10 (Right panel). The results confirm that Treg 
cells expansion upon leptin neutralization (fold increase) is negatively 
associated with EDSS score. This analysis also reveals that this association is 
not constant across the different quantiles of the EDSS. In particular the 
association is not significant until the 0.4 quantile (which corresponds in our 
data to an EDSS score of 1) and become stronger in the right tail of the EDSS 
distribution. For instance, in subjects with an EDSS score corresponding to the 
0.5 quantile (median), a 10% decrease of the Treg cells fold increase 
determines a 0.1 point increase in the corresponding quantile (i.e. the median 
value of the EDSS distribution raise by 0.1 point). An analogous 10% decrease 
of the Treg fold increase in proliferation will instead cause an increase of 0.3 
point in the 80th percentile of the EDSS distribution. 
 
 
           
 
        
 
Figure 10. MS patients regulatory T cells expansion inversely correlates with patients 
clinical status. (Left panel) The graph shows the fold increase in proliferation (expressed in 
ranks) of CD4+CD25highCD127- T cells purified from MS patients upon leptin neutralization, in 
patients with an EDSS<1, 2≤EDSS≤4 and EDSS>4. (Right panel) Estimated parameters (dots) 
with 95% confidence bands (gray area) in the quantile regression of  EDSS score by Treg cells 
fold increase in proliferation upon leptin neutralization. The vertical axis shows the values of 
the estimated parameter (fold increase in proliferation of Treg cells) in correspondence of the 
different quantiles of EDSS that are reported on the horizontal axis. Points are connected by 
dashes to visualize trends by outcome percentile. 
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Treg cells from MS patients showed an impaired in vivo and in vitro 
antigen-specific proliferation. 
 
Human Treg cells are anergic to in vitro anti-CD3 plus anti-CD28 stimulation 
but are highly proliferative in vivo (33). The proliferating index in vivo of the 
Treg cells was determined by assessing Ki67 expression. Treg cell from MS 
patients showed a reduced in vivo proliferation, when compared with healthy 
controls, confirmed by the lower expression of Ki67 (Fig. 11A and B). No 
differences in proliferation rate of effector T cells were observed between 
controls and MS patients (Fig. 12A and B).  
 
                          
                
Figure 11. Regulatory T cells from MS patients display a reduced proliferation in vivo. 
(A) Ki67 expression in freshly isolated CD4+Foxp3+ cells from healthy controls and MS 
patients. The data are shown as mean ± SEM (*p = 0.04). (B) Representative flow cytometry 
plots of Ki67 expression  in freshly isolated CD4+Foxp3+ cells from healthy control and MS 
patient.  
 
                                       
Figure 12. No differences in proliferation rate in vivo of effector T cells. (A) Ki67 
expression in freshly isolated CD4+Foxp3- cells from healthy controls and MS patients. The 
data are shown as mean ± SEM. (B) Representative flow cytometry plots of Ki67 expression  
in freshly isolated CD4+Foxp3- cells from healthy control and MS patient.  
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To evaluate the anti-mielin-specific proliferation of Treg cells, hMBP-specific 
short-term T-cell lines were generated. We measured the proliferative response 
against hMBP on Treg cells from MS patients and controls, moreover we 
added an anti-leptin blocking antibody to the culture medium. We observed a 
significant lower hMBP-specific response of Treg cells from MS patients when 
compared with healthy controls (Fig 13 A and B). Moreover Treg cells from 
MS patients showed an impaired expanding capacity even in presence of 
neutralizing leptin monoclonal antibody with respect to healthy controls (Fig 
13 C). We analyzed whether there could be differences in the proliferation rate 
against hMBP  and hMBP plus leptin neutralizing antibody of effector T cells 
between controls and patients. The responses of effector T cells  to h-MBP and 
to leptin neutralization were similar between controls and MS patients (Fig 13 
D). These data suggest that this is a Tregs specific defect in MS patients. 
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Figure 13. h-MBP specific proliferation of regulatory T cells from healthy controls and 
MS patients. (A) Percentage of CD4+FoxP3+ cells gated on CD4+ cells from healthy controls 
and MS patients stimulated with h-MBP in the presence or absence of leptin mAb. (*p = 0.03, 
**p = 0.004). (B) Percentage of increase of CD4+FoxP3+cells from healthy controls and MS 
patients upon h-MBP stimulation. The graph shows the mean of the percentage of  
CD4+FoxP3+ cells upon 7 days of h-MBP stimulation with respect to the percentage of 
CD4+FoxP3+ cells without stimulation (*p = 0.004). (C) Percentage of increase of 
CD4+FoxP3+cells from healthy controls and MS patients upon h-MBP + anti-Leptin 
neutralizing antibody stimulation. The graph shows the mean of the percentage of  
CD4+FoxP3+ cells upon 7 days of h-MBP + anti-Leptin stimulation with respect to the 
percentage of CD4+FoxP3+ cells upon h-MBP stimulation alone (*p = 0.03) The data are 
shown as mean ± SEM. (D) Percentage of CD4+FoxP3- cells gated on CD4+ cells from healthy 
controls and MS patients stimulated for 7 days with h-MBP in the presence or absence of leptin 
mAb. 
 
 
 
 
Inverse correlation between Tregs h-MBP-specific Expansion index and 
MS clinical severity. 
 
We next evaluated the relation between the myelin-specific proliferative 
capacity of Treg cells and the clinical status of MS patients. Disease severity of 
each patient was assessed clinically using the EDSS score, a method of 
quantifying disability in multiple sclerosis (67). We divided all patients in three 
groups on the basis of their EDSS value. We firstly evaluated the fold of 
increase in KI67 expression of Treg cells upon h-MBP stimulation to 
understand whether there could be a different h-MBP-specific proliferation of 
Treg cells in patients with a different EDSS. All three patient groups analyzed 
showed a similar antigen-specific Treg cells proliferation, indicating that the 
progression of pathology was not correlated with an altered h-MBP-specific 
Treg cells response (Fig 14A). We next evaluated the fold increase in KI67 
expression of Treg cells stimulated with h-MBP plus leptin neutralizing 
antibody with respect to Treg cells stimulated with h-MBP alone. On the 
contrary, in this case, we observed that MS patients with a lower EDSS 
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displayed an higher proliferative capacity of Treg, in response to h-MBP 
stimulation plus leptin neutralization when compared with patients whose 
clinical score was much more severe (Fig. 14B). Indeed patients with a lower 
EDSS score, showed a higher fold increase in KI67 expression when compared 
with patients with a more severe disease course (Fig. 14B).  
 
                        
 
 
Figure 14. MS patients regulatory T cells antigen-specific expansion inversely correlates 
with patients clinical status. (A) The graph shows the fold increase in Ki67 expression of 
CD4+ FoxP3+ T cells purified from MS patients upon h-MBP stimulation , in patients with an 
EDSS<1, 2≤EDSS≤4 and EDSS>4. The graph shows the mean of Ki67 expression of  
CD4+FoxP3+ cells upon 7 days of h-MBP stimulation with respect to the mean of Ki67 
expression of CD4+FoxP3+ cells without stimulation. (B) The graph shows the fold increase in 
Ki67 expression of CD4+ FoxP3+ T cells purified from MS patients upon h-MBP + leptin mAb 
stimulation, in patients with an EDSS<1, 2≤EDSS≤4 and EDSS>4. The graph shows the mean 
of Ki67 expression of  CD4+FoxP3+ cells upon 7 days of h-MBP leptin mAb stimulation with 
respect to the mean of Ki67 expression of CD4+FoxP3+ cells upon h-MBP stimulation alone 
(*p = 0.04). 
 
 
Multiple correlation matrix of  molecular variables in controls and MS 
patients. 
 
We performed a sophisticated mathematical model of data craft correlation 
matrix (Spearman rho non parametric correlation) among the molecular 
variables analyzed in the study in MS patients group stratified on the basis of 
EDSS score versus healthy controls. The results are presented in Fig.15. The 
controls group and patients groups showed significant differences in most of 
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variables analyzed. The results of the analysis showed that disease aggravation 
was correlated with a loss of a series of mechanisms of control. More 
specifically, we observed that, in controls group there was a strong positive 
correlation between the fold increase in proliferation of Treg cells upon leptin 
neutralization and the fold increase in IL-2 production (rho = 0.95, p= 0.001), 
in the same experimental condition (Fig. 15A). This correlation is less strong in 
patients with an EDSS minor than 2 (rho = 0.62, p = 0.007) (Fig. 15B) and is 
completely lost in patients with more severe disease (Fig. 15 C and D).  
 
 
 
 
                 A 
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Figure 15. Graphical representation of the Spearman rho non parametric correlation 
matrix among the analyzed variables in the (A)control subjects, (B) patients with EDSS < 
2, (C) patients with 2 ≤ EDSS ≤ 4,  (D) patients with EDSS > 4.The presence of a significant 
correlation between two variables is expressed by means of a red (negative correlation) or blue 
(positive correlation) ellipse while an empty circle refers to a non significant correlation. The 
colour intensity and the thickness of each ellipse are proportional to the correlation values. 
The graphs showes correlations among: proliferation of Treg cells stimulated with anti-
CD3/CD28 (indicated as Treg CD3/28); proliferation of Treg cells stimulated with anti-
CD3/CD28 plus leptin mAb (indicated as Treg CD3/28 + leptin mAb); fold increase in 
proliferation of Treg cells upon leptin neutralization (indicated as Treg expansion index); 
proliferation of effector T cells stimulated with anti-CD3/CD28 (indicated as Teff CD3/28); 
proliferation of effector T cells stimulated with anti-CD3/CD28 plus leptin mAb (indicated as 
Teff CD3/28 + leptin mAb); serum IL-2 levels; serum leptin levels; Treg cell IL-2 secretion 
upon anti-CD3/CD28 stimulation (indicated as IL-2 Treg CD3/28); Treg cell IL-2 secretion 
upon anti-CD3/CD28 plus leptin mAb stimulation (indicated as IL-2 Treg CD3/28+ leptin 
mAb); Fold increase in IL-2 production upon leptin neutralization in Treg cells (indicated as 
IL-2 fold increase in Treg); Effector T cell IL-2 secretion upon anti-CD3/CD28 stimulation 
(indicated as IL-2 Teff CD3/28); Effector T cell IL-2 secretion upon anti-CD3/CD28 plus 
leptin mAb stimulation (indicated as IL-2 Teff CD3/28 + leptin mAb); Effector T cell leptin 
secretion upon anti-CD3/CD28 stimulation (indicated as leptin Teff CD3/28); Effector T cell 
leptin secretion upon anti-CD3/CD28 plus leptin mAb stimulation (indicated as leptin Teff 
CD3/28 + leptin mAb); Treg cell leptin secretion upon anti-CD3/CD28 stimulation (indicated 
as leptin Treg CD3/28); Treg cell leptin secretion upon anti-CD3/CD28 plus leptin mAb 
stimulation (indicated as leptin Treg CD3/28+ leptin mAb). 
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In addition we observed that in the group of patients that displayed an EDSS 
minor than 2, there was an inverse correlation between Treg cells proliferation 
upon anti-CD3/CD28 stimulation and the fold increase in proliferation of Treg 
cells upon leptin neutralization (rho = -0.68, p < 0.001) (Fig.  15 B). In other 
words, the fold increase in proliferation of Treg cells upon leptin 
neutralization, is major as Treg cells are more hyporesponsive upon anti-
CD3/CD28 stimulation. This correlation is less strong in patients showed and 
EDSS between 2 and 4 (rho = -0.56, p = 0.007)  (Fig.  15 C), and was 
completely lost in patients with EDSS higher than 4 (Fig.  15 D).  
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Discussion  
 
 
Clonal deletion of self-reactive T cells in the thymus and induction of T-cell 
anergy alone do not explain the maintenance of immunologic self-tolerance, as 
potentially pathogenic autoreactive T cells are present in the periphery of 
healthy individuals (78,79). Thus, other regulatory mechanisms exist to prevent 
autoreactive T cells from causing immune disorders. Active suppression by 
regulatory T cells plays a key role in the control of self-antigen-reactive T cells 
and the induction of peripheral tolerance in vivo (80,81). Seminal experiments 
performed by Sakaguchi et al. (82) have shown that depletion of CD4+CD25+ 
suppressor cells results in the onset of systemic autoimmune diseases in mice. 
Furthermore, cotransfer of these cells with CD4+CD25– cells prevents the 
development of experimentally induced autoimmune diseases such as colitis, 
gastritis, insulin-dependent autoimmune diabetes, and thyroiditis (83). Human 
CD4+CD25hi T cells, similar to the mouse CD4+CD25+ suppressor cells, are 
anergic to in vitro antigenic stimulation and strongly suppress the proliferation 
of responder T cells upon co-culture (84). CD4+CD25+ T cells are among the 
best-characterized immune regulatory subsets shown to prevent activation and 
effector function of activated responder T cells (85). In these contests there are 
several studies performed to understand which is the alteration of this cellular 
subset occur during autoimmune diseases. However data from literature are a 
still controversial on the question whether qualitative more than quantitative 
alterations of Treg cells compartments, are responsible for the break of self-
immune tolerance.    
Indeed, previous studies have reported a significant decrease in the suppressive 
function of CD4+CD25hi Treg cells from peripheral blood of patients with MS 
as compared with healthy donors but no differences in the frequency of 
CD4+CD25hi Treg cells have been found between patients and healthy controls 
(86). On the other hand, other groups have shown that in patients with MS the 
compromised CD4+CD25high regulatory T-cell function is correlated with a 
reduced frequency of FOXP3-positive cells (87) but in the same time, an 
increased frequency of CD4+CD25+ regulatory T cells in the cerebrospinal 
fluid MS patients has been observed (88). To complicate this scenario there are 
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data suggesting that patients with the MS have only a strikingly reduced 
number of CD39+ and CD4+ CD25+ Treg cells in the peripheral blood (72,89).  
Since previous studies have showed that cloned CD4+ T cells could be induced 
to become regulatory if they were first rendered anergic and so that anergy of 
Treg cells correlates with suppressive function (90), in this study we firstly 
analyzed the anergic state of Treg cells from MS patients, with the attempt to 
find novel surrogate markers of immune tolerance. More specifically, we 
stimulated in vitro Treg cells purified from MS patients and healthy controls 
and we evaluated their proliferation after stimulation. Treg cells from MS 
patients showed a reduced in vitro hyporesponsiveness during TCR-induced 
stimulation resulting in a partial proliferation. This evidence was also 
supported by some low but consistent IL-2 secretion by Treg cells from MS 
patients in the same experimental conditions. This reduced in vitro 
hyporesponsiveness of Treg cells from MS patients could be partly responsible 
for the reduced in vitro suppressive function observed by other groups (86). 
We confirmed that leptin concentration was higher in sera of MS patients and 
that freshly isolated human Treg cells produce higher amounts of leptin with 
respect to effector T cells. No significant difference, in terms of leptin 
production, between Treg cells from MS patients and healthy controls was 
measured. 
We have reported that in vitro leptin neutralization results in proliferation of 
Treg cells purified from healthy controls during polyclonal anti-CD3/CD28 
stimulation (73). To further address whether the proliferative potential of Treg 
cells could be altered during MS, we analyzed the effect of leptin neutralization 
on proliferative capacity of this cellular subset in MS patients. We found that 
Treg cells from MS patients showed an impaired proliferation upon leptin 
neutralization. Indeed the fold increase in proliferation, mediated by leptin 
neutralization, of Treg cells from MS patients, has been shown to be lower 
when compared to that observed in healthy controls. As previously mentioned, 
the amount of leptin produced by Treg cells was the same in patients and 
controls, thus suggesting that the impaired proliferative potential of Treg cells 
could not be ascribed to the amount of leptin produced by Treg cells but rather 
to an intrinsic alteration of proliferation of these cells during MS. Once again, 
these data are confirmed by IL-2 secretion. Indeed, we observed in Treg from 
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MS patients a lower fold increase in IL-2 production upon leptin neutralization 
when compared to that observed in healthy controls, supporting the hypothesis 
that  Treg cells are characterized by an altered response to leptin neutralization 
during MS. It is important to note that no differences in effector T cells 
proliferation and IL-2 secretion between controls and patients where found, 
confirming that the break of self antigen tolerance is mediated by alterations 
regarding specifically Treg cells compartment.  
It has been shown that Treg cells leptin-neutralization induced proliferation is 
IL-2 dependent (73). We evaluated the correlation between the fold increase in 
proliferation and the fold increase in IL-2 production of Treg cells upon leptin 
neutralization. In healthy controls there is a linear positive correlation between 
the two parameters analyzed, confirming the presence of an autocrine 
stimulatory  loop in which IL-2 sustains the expansion of Treg cells. In MS 
patients there is a loss of this correlation indicating that the proliferation of  
Treg cells, although very mild, is not supported by an increase in IL-2 
production. It is possible to speculate that in MS patients Treg cells are 
characterized by alteration in IL-2/IL-2R pathway. Further studies are being 
performed to address this point. 
In spite of intensive studies to understand which is the alteration occurs during 
autoimmune diseases, so far there are not reliable surrogate markers of immune 
tolerance capable of detecting the loss of self-tolerance in autoimmunity and 
MS.  
In this context, there is no means to identify a priori those MS patients who 
will have a good progression of disease (in terms of relapses and EDSS score) 
and those who will have a worst MS course. In other words we do not have 
either predictive markers able to predict the clinical progression in MS or the 
clinical response to classical therapeutic regimes. In this study, we also aimed 
at developing reliable and reproducible in vitro assay capable of detecting 
tolerance state in MS patients and possibly to anticipate clinical progression 
towards a worse disease. We observed that leptin-neutralization induced Treg 
cells proliferation is higher in patients with a better clinical score assessed 
using the Expanded Disability Status Scale (EDSS). We observed that MS 
patients with a lower EDSS displayed an higher expansion index of Treg cells 
upon leptin neutralization when compared with patients whose clinical score 
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was much more severe, indicating that the progression of pathology 
compromises the proliferative potential of Treg cells or that impaired Treg 
cells expansion could be associated with a worse clinical progression of MS. In 
other words Treg cells expansion upon leptin neutralization (fold increase) is 
negatively associated with EDSS score. These findings envision new 
possibilities of using the anti-leptin-based Treg cell expansion index in  
evaluation of immune tolerance and to predict clinical progression in MS 
patients. These data were confirmed not only in non-antigen specific conditions 
during CD3/CD28 stimulations but also in myelin-specific assays by using 
anti-h-MBP responses, thus suggesting that it is likely that in MS there is a 
reduced capacity of Tregs to respond towards h-MBP likely impairing their 
capacity to control CNS immune tolerance. 
It is interesting to note that also Treg cells antigen-specific expansion index 
inversely correlated with patients clinical status, supporting the hypothesis that 
Treg cells proliferation rate (policlonal or antigen-specific) could be related 
with clinical progression of disease. 
Finally, in order to evaluate the alterations occurring in MS patients and the 
differences characterizing MS patients with different EDSS score, we 
performed a multiple Spearman rho non parametric correlation matrix among 
the molecular variables analyzed in the study in both controls and patients. We 
found a marked difference between controls and patients indicating that a 
series of mechanisms of control are altered during disease compromising the 
correlation that are physiologically present in healthy individuals. Moreover 
the analysis reveals that the progression of disease, evaluated as EDSS score, is 
associated with a further alteration of  these correlations. Indeed, there is a 
strong difference, in terms of correlations, among the three groups of patients 
(separated on the basis of EDSS score) analyzed. 
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Conclusions 
 
 
We believe that the Treg cell expansion index can represent a valuable and 
repeatable assay to measure immune tolerance and disease progression in MS. 
We are putting all the effort to translate this assay in clinical practice and to 
measure immune tolerance also in other autoimmune diseases such as type 1 
diabetes and intestinal bowel disease. Future investigations and prospective 
studies will provide sufficient evidence for the application of our results. 
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